These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11432901)

  • 1. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
    Baculi RH; Suki S; Nisbett J; Leeds N; Groves M
    J Clin Oncol; 2001 Jul; 19(13):3297-8. PubMed ID: 11432901
    [No Abstract]   [Full Text] [Related]  

  • 2. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
    Platini C; Long J; Walter S
    Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
    [No Abstract]   [Full Text] [Related]  

  • 3. Correction: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
    Pestalozzi BC
    J Clin Oncol; 2001 Oct; 19(20):4091. PubMed ID: 11600616
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
    Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
    [No Abstract]   [Full Text] [Related]  

  • 5. Intrathecal trastuzumab: dose matters.
    Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
    Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab for breast cancer-related carcinomatous meningitis.
    Robins HI; Liu G; Hayes L; Mehta M
    Clin Breast Cancer; 2002 Jan; 2(4):316. PubMed ID: 11899365
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
    Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
    J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
    Colozza M; Minenza E; Gori S; Fenocchio D; Paolucci C; Aristei C; Floridi P
    Cancer Chemother Pharmacol; 2009 May; 63(6):1157-9. PubMed ID: 18987856
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.
    Laufman LR; Forsthoefel KF
    Clin Breast Cancer; 2001 Oct; 2(3):235. PubMed ID: 11899418
    [No Abstract]   [Full Text] [Related]  

  • 14. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
    Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
    Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after brain metastases from breast cancer in the trastuzumab era.
    Kirsch DG; Ledezma CJ; Mathews CS; Bhan AK; Ancukiewicz M; Hochberg FH; Loeffler JS
    J Clin Oncol; 2005 Mar; 23(9):2114-6; author reply 2116-7. PubMed ID: 15774813
    [No Abstract]   [Full Text] [Related]  

  • 16. [Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer].
    Ayuga Loro F; Jiménez Caballero PE; Martínez Barbeito MB; Cruz Mora MA
    Med Clin (Barc); 2009 Jul; 133(7):279-80. PubMed ID: 19615485
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
    Altundag K; Altundag O; Atik MA; Morandi P; Gunduz M
    Breast; 2005 Oct; 14(5):425. PubMed ID: 16216749
    [No Abstract]   [Full Text] [Related]  

  • 18. [Trastuzumab and blood-brain barrier].
    Platini C
    Bull Cancer; 2007 Oct; 94(10):857-9. PubMed ID: 17964978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab in CSF.
    Pestalozzi BC; Brignoli S
    J Clin Oncol; 2000 Jun; 18(11):2349-51. PubMed ID: 10829059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.